Asset profile
SCM-AGH
Cell therapy
Evidence outlook · lead readout
NCT04179760 · Dermatitis, Atopic
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04179760: The study included 92 participants and used a randomized, placebo-controlled design, with the Phase II portion described as quadruple-blind; however, the Phase I portion was open-label. Because the primary EASI-50 result is not available, it is not possible to determine whether the endpoint was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.